Ottawa-Shanghai Joint School of Medicine


SU Yingjie

Associate chief pharmacist


Tel: 13764566588

Research: Antitumor drugs clinical pharmacy


Anti-tumor drug clinical pharmacist in Renji hospital

Lecturer at Ottawa-Shanghai joint school of Medicine 

Teacher in Clinical pharmacist training base of Chinese Hospital Association

Member of the Anti-tumor Professional Group of Clinical Pharmacy Branch of Shanghai Medical Association

Member of anti-tumor Professional Group of Clinical Pharmaceutical Management Professional Committee of Shanghai Hospital Association

As associate chief pharmacist in Renji hospital, Su Yingjie is responsible for the drug therapy strategy and management for tumor patients with complex drugs and organ dysfunction, drug interactions, adverse drug reactions and management of cancer pain patients. 

So far, Su Yingjie has been engaged in the clinical pharmacy work of anti-tumor drugs for more than 10 years, and has published more than 7 SCI papers and more than 10 papers in Chinese core journals as the first author or the corresponding author. Also Su Yingjie has participated in 3 monographs, presided over and participated in nearly 8 municipal Science and Technology Commission funded projects. The papers have won the award of “Excellent paper” in the annual meeting of Clinical Pharmacy Branch of Chinese Medical Association. 

Su Yingjie is the recipient of many awards and honors including Excellent Clinical Pharmacist of Shanghai Medical Association, Excellent Young Pharmacist of Shanghai Pharmaceutical Association and Excellent Teacher of Shanghai Clinical pharmacist in on-the-job Training.


  • Ying-Jie Su, Yi-Dan Yan, Wen-Juan Wang, Tao Xu, Zhi-Chun Gu, Yong-Rui Bai, Hou-Wen Lin. Drug-related problems among hospitalized cancer pain patients: an investigative single-arm intervention trial [J] . Ann Palliat Med. 2021 Feb;10(2):2008-2017.

  • Yingjie Su, Jie Fu, Jiangyang Du, Bin Wu. First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis [J]. Ther Adv Med Oncol. 2020 Aug 17; 12: 1758835920950199.

  • Ying-Jie Su, Yi-Dan Yan, Wen-Juan Wang, Tao Xu, Zhi-Chun Gu, Yong-Rui Bai, Hou-Wen Lin. Preliminary exploration on the role of clinical pharmacists in cancer pain pharmacotherapy [J]. Ann Palliat Med. 2020 Sep;9(5):3070-3077.

  • Yang-Xi Liu, Ke-Jia Le, Chi Zhang, Min Cui, Hong Zhou, Ying-Jie Su, Zhi-Chun Gu. A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report [J]. Transl Cancer Res .2020 Jan; 9(1): ‏ 382-387.

  • Yi-Dan Yan, Ying-Jie Su, Bo-Ya Chen, Jiu-Jie Cui, Zai-Li Zhang, Qi Xu, Zhi-Chun Gu. The optimal anticoagulant therapy for mechanical heart valves in a gallbladder cancer patient with hepatic metastases: A case report [J]. Medicine (Baltimore). 2018 Sep;97(37) : e12368.

  • Zhi-Chun Gu, Yi-Jing Zhang, Mang-Mang Pan, Chi Zhang, Xiao-Yan Liu, An-Hua Wei, Ying-Jie Su. The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis [J]. Medicine (Baltimore). 2018 Mar; 97(11): e0122.